-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today announced that the external Safety Review Committee recommended that the Company’s Phase 1/1b open label study to assess the safety, t ...

TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) is pleased to announce the successful completion of its first gold sale from its 100% owned Bralorne Gold Project in British Columbia (“Bralorne”). The Company sold 707 ounces of gold in August, generating gross proceeds of approximately US$2.3 million. This first gold sale marks a key milestone for Talisker, confirming its shift from an advanced-stage developer to an active gold produc ...

Company to highlight ongoing AXPAXLI™ wet AMD registrational program, strategy and next steps in NPDR and DME, and global commercial opportunity for AXPAXLI Event to feature global retinal disease experts Dr. Arshad M. Khanani MD, MA, FASRS; Professor Adnan Tufail, MBBS, MD, FRCOphth; Dr. Eleonora Lad, MD, PhD; and Dr. Patricio G. Schlottmann, MD The live event will take place in New York City on September 30, 2025, at 2:00 PM ET BEDFORD, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (N ...

TUCSON, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that Patrick NJ Schnegelsberg, Chief Executive Officer, will present in-person at the H.C. Wainwright 27th Annual Global Investment Conference being held both in-person and virtually from September 8 -10, 2025 at the Lotte New York Palace Hotel. Presentation information is below: H.C. Wainwright Annual Global Investment Conference Presentation date: September 10thPresentat ...

iMDx’s ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it is actively enrolling patients in its clinical trial to assess GraftAssureDx and that last week, it enrolled the first patient. In addition, the official clinical trial listing now names 10 le ...

Multi-Million Dollar, Non-Dilutive Facility Supports SemiCab’s Three Largest Global Customers Fort Lauderdale, FL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. (“Algorhythm”) (NASDAQ: RIME), an AI technology holding company, announced today that its subsidiary, SMCB Solutions Private Limited (“SemiCab India), has secured a supply chain finance receivables facility with Bank of America. The facility provides SemiCab India with access to low-cost, non-dilutive working capital by enabling acce ...

Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for fibromyalgia in over 15 years Two pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared to placebo Tonmya showed consistent improvements across core fibromyalgia symptoms, including widespread pain, sleep disturbance and fatigue Tonmya was well tolerated, supporting its potential as a long-term treatment option for fibromyalgia Tonmya is expe ...

The high-efficiency solution for broadcasters of live events, enabling to reduce CDN costs by up to 50%, will be presented at IBC 2025 in Amsterdam, the Netherlands Herzliya, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd. (NASDAQ: BMR), a leader in video optimization technology and solutions, today announced it will demonstrate real-time, cost-effective AI-powered quality enhancement to 4K for broadcasters and streamers of live events, such as sports matches and music concerts. This solution ...

核心观点 - ECARX的Pikes计算平台和Cloudpeak跨域软件栈首次在领克10 EM-P插电混动轿车中集成 标志着AI智能座舱技术的新突破 [1][2] - 该技术合作强化了ECARX在汽车智能化领域的技术领导地位 并推动全球汽车行业向全智能出行转型 [3] 技术合作与产品特性 - 领克10 EM-P采用5纳米高通Snapdragon SA8295P车规级SoC 配合ECARX的Pikes计算平台提供硬件支持 [2] - Cloudpeak软件栈整合仪表盘、HUD、中控屏、车辆控制和ADAS系统 最大化发挥SoC潜力 [2] - 实现AI代理、3D环绕现实(SR)、哨兵模式、后扰流板控制、自动风口调节及多品牌手机-座舱互联等高级功能 [2] - 搭载LYNK Flyme Auto 2操作系统 提升智能化和用户体验 [2] 公司背景与业务规模 - ECARX为全球汽车技术供应商 提供从SoC到中央计算平台及软件的智能汽车一站式解决方案 [4] - 公司成立于2017年 2022年纳斯达克上市 在13个主要地区拥有超1600名员工 覆盖中国、欧美及东南亚市场 [5] - 联合创始人包括董事长兼CEO沈子瑜和吉利控股集团创始人李书福 合作品牌涉及领克、路特斯、极星、smart、沃尔沃等 [5] - 产品已应用于全球超930万辆汽车 并与大众集团、一汽集团、东风标致雪铁龙等知名车企合作 [5] 战略定位与行业影响 - 技术整合体现ECARX工程执行能力 推动智能座舱产品组合进入量产阶段 [3] - 公司致力于研发路线图 确保全球车企保持技术领先优势 [3] - 为电动车架构开发全栈解决方案 旨在提升用户体验并降低复杂度与成本 [4]

Significant Development in the Estimated $30 Billion Global Infection-Prevention Market SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance (PTOL-85) for its patent application titled, “Antipathogenic Fibrous Materials.” The patent secures broad protection for SINTX’s proprietary silicon nitride–based antipathogen platform. This ...